You are here
Circulating Anti-Mullerian Hormone Levels May Predict Blastocyst Formation Rates In Donor IVF Cycles
by Jennifer H. Gilbert, Jennifer C. Settle, John E. Nichols, Tyl H. Taylor, J. D. Wininger, and William E. Roudebush
Anti-Mullerian Hormone (AMH) is a glycoprotein dimer composed of two 72kDa monomers linked by disulfide bridges and is a member of the transforming growth factor-super family. AMH is produced in small amounts by ovarian granulosa cells after birth until menopause, and then becomes undetectable. AMH performs various physiological functions, e.g. controlling antral follicle development. AMH is routinely used clinically to help determine ovarian reserve status and subsequently, gonadotropin stimulation protocols. Whereas, AMH values can help predict the quantity of oocytes obtained during retrieval, little to no information is available regarding AMH levels on embryo formation rates.
The objective of this study was to determine if circulating anti-mullerian hormone (AMH) levels relate to blastocyst formation rates following ovarian stimulation in donor IVF cycles.
The data demonstrates a significant and positive correlation between circulating AMH levels in oocyte donors and blastocyst formation rates. This is the first report demonstrating a significant relationship between AMH and blastocyst formation rates.